Skip to main content

GSK Proposes Reconsideration In Zofran Lawsuits

GSK Proposes Reconsideration In Zofran Lawsuits

GSK Proposes Reconsideration In Zofran Lawsuits

Introduction

GlaxoSmithKline has requested the federal judge presiding over all federal Zofran birth defect lawsuits to revisit the preemption defense, based on a recent ruling by the U.S. Supreme Court.

According to the court documents, the plaintiffs have alleged GSK failed to provide sufficient pregnancy warnings on Zofran, which is commonly prescribed for symptoms of morning sickness. The drugmaker previously tried to dismiss the case, arguing that the claims are preempted by federal law since the FDA would not have allowed a pregnancy warning. However, U.S. District Judge Dennis Saylor issued a memorandum and order on February 5, denying summary judgment motion filed by GlaxoSmithKline to toss all Zofran birth defect lawsuits and allowed a group of cases to prepare for early bellwether trials.

More than 468 lawsuits have been filed against GSK alleging that the company knew about Zofran's pregnancy risks for several years yet failed to adequately warn the medical fraternity. Zofran lawsuits were centralized in October 2015, before Judge Dennis F. Saylor as a part of a multidistrict litigation (MDL No. 2657; In Re: Zofran (Ondansetron) Products Liability Litigation) in the District of Massachusetts.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!